1. Pink Sheet
  2. >>Geography
  3. >>Europe

Price-Based Procurement Could Be Pushing Down Vaccination Coverage

More Flexibility Needed In Purchasing Mechanisms

 
• By Francesca Bruce

A new study argues that certain procurement methods could be hitting vaccine coverage rates and that wider debate is needed among policy makers, payers and procurers to find more sophisticated purchasing models.

Medical concept Vaccination vaccine vial dose flu shot drug needle syringe,Lab test research science hypodermic injection treatment disease care hospital prevention immunization illness disease baby.
Procurement Of Vaccines Should Not Focus Solely On Price • Source: Shutterstock

Procurement models like price-based tendering could be to blame for a decline in vaccine coverage rates, argues an analysis published in the peer-reviewed journal Expert Review of Vaccines. Models that allow more flexibility and focus on factors beyond price, such as value-added services that counter anti-vaccination campaigns, can help contribute to a sustainable “vaccine ecosystem,” it says.

“There is certainly a correlation between the use of some forms of tendering and procurement and reduction in the level of coverage,” according to Tim Wilsdon, vice president in the Life Sciences Practice at the global consulting firm CRA,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

More from Geography

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.